Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > T2 Data Release

<< Previous

Bullboard Posts

Next >>

Post by Danny1082Manon Aug 09, 2020 8:05pm

271 Views

Post# 31385309

T2 Data Release

Though the PR said expect T2 topline data "on or before Aug 31st", which is a Monday, we know they will have in hand well before that. If it meets it's primary endpoint I would expect "before" the 31st during the week of 8/24. If it fails they will release on 8/31 to keep the ATM churning to raise equity. Why would they hold good data at this point. Hopefully there is run on the share price week of 8/24. Waiting until Monday August 31st would smell like a failure to me

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle